Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United Kingdom.

McCrone P, Payan CA, Knapp M, Ludolph A, Agid Y, Leigh PN, Bensimon G; NNIPPS Study Group..

PLoS One. 2011;6(9):e24369. doi: 10.1371/journal.pone.0024369. Epub 2011 Sep 8.

2.

Cost-of-illness in multiple system atrophy and progressive supranuclear palsy.

Winter Y, Stamelou M, Cabanel N, Sixel-Döring F, Eggert K, Höglinger GU, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R, Spottke AE.

J Neurol. 2011 Oct;258(10):1827-34. doi: 10.1007/s00415-011-6028-7. Epub 2011 Apr 10.

PMID:
21479850
3.

Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia.

Kanazawa M, Tada M, Onodera O, Takahashi H, Nishizawa M, Shimohata T.

Parkinsonism Relat Disord. 2013 Dec;19(12):1149-51. doi: 10.1016/j.parkreldis.2013.07.019. Epub 2013 Aug 3.

PMID:
23916652
4.

Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale.

Payan CA, Viallet F, Landwehrmeyer BG, Bonnet AM, Borg M, Durif F, Lacomblez L, Bloch F, Verny M, Fermanian J, Agid Y, Ludolph AC, Leigh PN, Bensimon G; NNIPPS Study Group..

PLoS One. 2011;6(8):e22293. doi: 10.1371/journal.pone.0022293. Epub 2011 Aug 4.

5.

Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN; NNIPPS Study Group..

Brain. 2009 Jan;132(Pt 1):156-71. doi: 10.1093/brain/awn291. Epub 2008 Nov 23.

6.

Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy.

Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC.

Brain. 2006 Apr;129(Pt 4):1040-9. Epub 2006 Feb 2.

PMID:
16455792
7.

Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy.

Reginold W, Lang AE, Marras C, Heyn C, Alharbi M, Mikulis DJ.

Parkinsonism Relat Disord. 2014 Feb;20(2):222-5. doi: 10.1016/j.parkreldis.2013.10.002. Epub 2013 Oct 12.

PMID:
24239142
8.

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

O'Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, Revesz T, Lees AJ.

Brain. 2008 May;131(Pt 5):1362-72. doi: 10.1093/brain/awn065. Epub 2008 Apr 2.

PMID:
18385183
9.

Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.

Brown RG, Lacomblez L, Landwehrmeyer BG, Bak T, Uttner I, Dubois B, Agid Y, Ludolph A, Bensimon G, Payan C, Leigh NP; NNIPPS Study Group..

Brain. 2010 Aug;133(Pt 8):2382-93. doi: 10.1093/brain/awq158. Epub 2010 Jun 24.

PMID:
20576697
11.

Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom - findings from the European Schizophrenia Cohort (EuroSC).

Heider D, Bernert S, König HH, Matschinger H, Hogh T, Brugha TS, Bebbington PE, Azorin M, Angermeyer MC, Toumi M.

Eur Psychiatry. 2009 May;24(4):216-24. doi: 10.1016/j.eurpsy.2008.12.013. Epub 2009 Mar 28.

PMID:
19328658
12.

Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.

Numao A, Suzuki K, Miyamoto M, Miyamoto T, Hirata K.

Parkinsonism Relat Disord. 2014 Feb;20(2):212-6. doi: 10.1016/j.parkreldis.2013.11.005. Epub 2013 Nov 14.

PMID:
24280021
13.

Symptom prevalence, severity and palliative care needs assessment using the Palliative Outcome Scale: a cross-sectional study of patients with Parkinson's disease and related neurological conditions.

Saleem TZ, Higginson IJ, Chaudhuri KR, Martin A, Burman R, Leigh PN.

Palliat Med. 2013 Sep;27(8):722-31. doi: 10.1177/0269216312465783. Epub 2012 Dec 3.

PMID:
23208011
14.

Clinical speech impairment in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy.

Sachin S, Shukla G, Goyal V, Singh S, Aggarwal V; Gureshkumar., Behari M.

Neurol India. 2008 Apr-Jun;56(2):122-6.

15.
16.

Pain in multiple system atrophy and progressive supranuclear palsy compared to Parkinson's disease.

Kass-Iliyya L, Kobylecki C, McDonald KR, Gerhard A, Silverdale MA.

Brain Behav. 2015 May;5(5):e00320. doi: 10.1002/brb3.320. Epub 2015 Mar 25.

17.
18.

Health-related quality of life in multiple system atrophy and progressive supranuclear palsy.

Winter Y, Spottke AE, Stamelou M, Cabanel N, Eggert K, Höglinger GU, Sixel-Doering F, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R.

Neurodegener Dis. 2011;8(6):438-46. doi: 10.1159/000325829. Epub 2011 May 12.

PMID:
21576919
19.

Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy.

Han YH, Lee JH, Kang BM, Mun CW, Baik SK, Shin YI, Park KH.

J Neurol Sci. 2013 Feb 15;325(1-2):29-35. doi: 10.1016/j.jns.2012.11.009. Epub 2012 Dec 20.

PMID:
23260321
20.

Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.

Rusz J, Bonnet C, Klempíř J, Tykalová T, Baborová E, Novotný M, Rulseh A, Růžička E.

J Neurol. 2015;262(4):992-1001. doi: 10.1007/s00415-015-7671-1. Epub 2015 Feb 17.

PMID:
25683763

Supplemental Content

Support Center